Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9UBS4
UPID:
DJB11_HUMAN
Alternative names:
APOBEC1-binding protein 2; DnaJ protein homolog 9; ER-associated DNAJ; ER-associated Hsp40 co-chaperone; Endoplasmic reticulum DNA J domain-containing protein 3; HEDJ; Human DnaJ protein 9; PWP1-interacting protein 4
Alternative UPACC:
Q9UBS4; Q542Y5; Q542Y9; Q6IAQ8; Q96JC6
Background:
DnaJ homolog subfamily B member 11, known by alternative names such as APOBEC1-binding protein 2 and ER-associated DNAJ, plays a crucial role in protein homeostasis. It acts as a co-chaperone for HSPA5, essential for the proper folding, trafficking, or degradation of proteins. This protein binds directly to unfolded proteins and nascent peptide chains, facilitating their maturation and correct trafficking, notably for PKD1.
Therapeutic significance:
The protein's involvement in Polycystic kidney disease 6, characterized by cyst formation in kidneys and potentially the liver, underscores its therapeutic significance. Understanding the role of DnaJ homolog subfamily B member 11 could open doors to potential therapeutic strategies for treating this autosomal dominant disorder.